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Abstract
Tuberculosis (TB) remains a major international health problem. Rapid differentiation of Mycobacterium tuberculosis complex
(MTB) from non-tuberculous mycobacteria (NTM) is critical for decisions regarding patient management and choice of
therapeutic regimen. Recently we developed a 20-compound model to distinguish between MTB and NTM. It is based on
thermally assisted hydrolysis and methylation gas chromatography-mass spectrometry and partial least square discriminant
analysis. Here we report the validation of this model with two independent sample sets, one consisting of 39 MTB and 17
NTM isolates from the Netherlands, the other comprising 103 isolates (91 MTB and 12 NTM) from Stellenbosch, Cape Town,
South Africa. All the MTB strains in the 56 Dutch samples were correctly identified and the model had a sensitivity of 100%
and a specificity of 94%. For the South African samples the model had a sensitivity of 88% and specificity of 100%. Based on
our model, we have developed a new decision-tree that allows the differentiation of MTB from NTM with 100% accuracy.
Encouraged by these findings we will proceed with the development of a simple, rapid, affordable, high-throughput test to
identify MTB directly in sputum.
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Introduction
Tuberculosis (TB) remains a major international health threat,
with 8.7 million new cases and 1.4 million deaths in 2011 [1]. The
global emergence of both human immunodeficiency virus (HIV)
infection and multidrug resistant TB (MDR-TB) poses significant
threats to TB control. An estimated 13% of new TB cases occur in
those infected with HIV [1]. Up to 10% of people with latent TB
will develop active disease [2], but HIV co-infection might
increase this risk almost 40 fold [3–5]. Several methods are
available for the diagnosis of TB, but all have limitations [6–8].
Worldwide, direct identification of mycobacteria in sputum using
Ziehl-Neelsen staining and microscopy is still the most commonly
used method. However, the sensitivity of the test varies consid-
erably between 30 and 70% [8]. Furthermore the Ziehl-Neelsen
test cannot distinguish Mycobacterium tuberculosis complex (MTB)
from non-tuberculous mycobacteria (NTM). Rapid culture
systems have been developed, for example, the Mycobacteria
Growth Indicator Tube (MGIT) method [9] and the Microscopic
Observation Drug Susceptibility assay [10]. Again these tests do
not differentiate between MTB and NTM. This distinction,
however, is essential to ensure the correct choice of therapy.
The diagnosis of TB is more complicated in HIV-positive
persons because of a higher frequency of negative and pauciba-
cillary sputum smears (i.e negative Ziehl-Neelsen test) [11]. In a
study in Khayelitsha, a district in Cape Town, South Africa, 49%
of HIV-positive patients on TB treatment had a negative smear
although the sputum culture was positive [12]. Thus time-
consuming culture is still necessary to confirm a diagnosis of TB
in HIV positive patients [13]. Since it can take up to three weeks to
obtain results from culture using the traditional phenotypic
diagnostic techniques to distinguish MTB from NTM [6], there
is a great need for a rapid, affordable and sensitive method for the
early diagnosis of TB that will then allow appropriate and effective
therapy.
NTM are an increasing problem, particularly for those with
HIV or chronic lung disease [14,15]. In patients with suspected
tuberculosis in Cape Town, South Africa, NTM rather than MTB
were grown from approximately 10% of the culture-positive but
smear-negative sputum samples [16]. Modern nucleic acid
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amplification techniques rapidly distinguish MTB from NTM, but
these techniques are not widely available in resource-limited
settings due to the high cost and lack of infrastructure and
expertise. Diagnostic delay contributes to ongoing transmission
and poor clinical outcomes. There are commercially available gas
chromatography techniques for distinguishing different types of
mycobacteria. However, these do not lend themselves to further
development for use in resource-constrained countries.
Recently we described a new approach for the identification of
biomarkers to differentiate MTB from NTM in early cultures. We
used thermally-assisted hydrolysis and methylation followed by gas
chromatography-mass spectrometry (THM-GC-MS) and chemo-
metrics [17]. Our aim is to develop an affordable and practical test
using these biomarkers for the direct identification of mycobacteria
in sputum and to apply this technology in a portable device. This
would allow the rapid classification of patients with suspected TB
into three categories: those with MTB, those with NTM and those
with no mycobacteria in their sputum. Our model identified 20
compounds that could distinguish 15 MTB from 29 NTM
cultivated strains with 95% accuracy. To further test the model
we describe here its application to 56 well-characterized myco-
bacterial isolates from patients in the Netherlands and 103




Fifty-six mycobacterial strains were obtained from patients in
the Netherlands, and identified at the National Institute for Public
Health and the Environment (RIVM) in the Netherlands (Table 1).
These constitute Testset-1. In the Netherlands all hospitals are
required by law to send all mycobacterial isolates, whether MTB
or NTM, to the Dutch Mycobacteria Reference Laboratory at the
RIVM for species determination, drug susceptibility testing and
strain typing for contact investigations. The 56 strains were
selected by the RIVM to provide representative examples of the
MTB and NTM strains found in the Netherlands. The strains
were cultured using the Mycobacteria Growth Indicator Tube
(MGIT) culture system (MGIT, BD Diagnostics, Detroit, MI,
USA). The species was determined using the line probe assay
(GenoType Mycobacterium, Hain Life Science GmbH, Nehren,
Germany). A separate set, Testset-2, consisting of 103 mycobac-
terial isolates was obtained from patients with suspected pulmo-
nary TB in Stellenbosch, Cape Town, South Africa (Table 2).
These strains were cultured from sputum samples using the
manual BACTEC MGIT reader. A positive MGIT result was
confirmed by the Bioline test SD TB Ag MPT64 (Standard
Diagnostics Inc, Kyonggi-do, South Korea) to discriminate
between MTB and NTM and the species was subsequently
determined by 16S ribosomal RNA sequencing (3730XL Genetic
Analyzer, Applied Biosystems, Carlsbad, CA, USA). The MGIT
tubes were labelled with a code and later shipped to Amsterdam
on dry ice.
Sample preparation for thermochemolysis GC-MS
All samples were tested blindly without foreknowledge of
whether they contained MTB or NTM. The pellets in the positive
MGIT tubes were collected by a sterile Pasteur pipette, and
transferred to a 2 mL screw cap vial. The mycobacteria were
killed by heating for 20 min at 80uC and the tube was centrifuged
at 12,0006g for 10 min. The bacterial pellets were washed with
deionized water under the same conditions. The washed pellets
were resuspended in deionized water to a concentration of
approximately 66108 bacteria/mL (Mc Farland turbidity 2).
Fifteen microliters of the sample was used for the THM-GC-MS
analysis.
Reagents
A 25% tetramethyl ammonium hydroxide (TMAH) solution in
methanol was obtained from Sigma–Aldrich (Zwijndrecht, The
Netherlands). Before use the solution was diluted ten times with
deionized water obtained from a Sartorius Arium 611 UV water
purification device (Sartorius, Nieuwegein, The Netherlands). The
solution was stable for two weeks at room temperature.
Instrumentation
All THM–GC–MS experiments were carried out on a
Shimadzu GCMS-QP2010 (Shimadzu, Den Bosch, The Nether-
lands). The GC system was equipped with a ‘‘Focus’’ XYZ robotic
auto sampler and an Optic 3 Programmed Temperature
Vaporizing (PTV) injector (ATAS GL, Eindhoven, The Nether-
lands).
Automated THM-GC-MS procedure
The automated THM-GC-MS procedure has been described
previously [18]. In brief, 15 mL of each mycobacterial suspension
was first injected into the PTV injector at 40uC. The injector was
then rapidly heated to 120uC to eliminate water while retaining
the sample in the sintered-bed liner inside the injector. After
cooling the injector to 40uC, 20 mL of the 2.5% TMAH reagent
was injected to cover the whole bacterial sample. Subsequently,
the injector was heated to 120uC to remove the solvent and
incubate the residue present in the sintered-bed of the liner. The
injector temperature was then increased to 450uC to perform
thermochemolysis. After 5 min the injector temperature was
decreased and maintained at 320uC until the end of the GC run.
All GC analyses were performed on a TC 5MS column (GL
Sciences, Tokyo, Japan) of 30 m60.25 mm internal diameter,
Table 1. The 56 mycobacterial strains from The Netherlands
obtained via The National Institute for Public Health and the
Environment (RIVM).
33 strains M. tuberculosis 2 strains M. gordonae
2 strains M. africanum 2 strains M. kansasii type I
2 strains M. bovis spp bovis 2 strains M. malmoense
2 strains M. bovis BCG 1 strain M. abscessus
2 strains M. avium complex 1 strain M. haemophilum
2 strains M. chelonae complex 1 strain M. simiae
2 strains M. fortuitum complex 1 strain M. marinum
1 strain M. intracellulare
doi:10.1371/journal.pone.0076263.t001
Table 2. 103 primary isolates from Stellenbosch, Cape Town,
South Africa.
91 strains M. tuberculosis 2 strains M. avium
2 strains M. intracellulare 1 strain M. lentiflavum
2 unknown NTM strains Bioline test Negative 2 strains M. gordonae
2 strains M. peregrinum/M. septicum 1 strain N. shimofusensis
doi:10.1371/journal.pone.0076263.t002
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coated with 0.25 mm of a 5% phenyl-methylpolysiloxane station-
ary phase. Helium was used as the carrier gas. The separation was
performed by starting the GC oven at 40uC for 3 min, followed by
a first ramp of 20uC/min to 100uC with a hold of 7 min, and then
a second ramp of 5uC/min to 320uC with a final hold of 6 min.
The MS was operated in the full scan mode collecting spectra at a
rate of 5 Hz over the mass window from 60 to 500 amu. All
samples were randomly and blindly tested.
Chemometric method
The partial least square discriminant analysis (PLS-DA) model
we developed to classify samples as NTM or MTB is based on the
(relative) concentration levels of 20 compounds in the THM-GC-
MS chromatograms [17]. Briefly; to classify an unknown sample, a
THM-GC-MS chromatogram is recorded for the sample and the
peak areas of the 20 target compounds are integrated at specific
mass channels. Then the areas are normalized to give a total sum
of 1 and the following equation is applied:V~
X20
i~1
bi  ai, where
bi are the coefficients provided in Table 3 and ai are the
normalized areas for the 20 compounds as measured from the
target m/z fragment. The value of V is then compared with the
threshold value. The threshold value is determined by the so-called
cost function, i.e. by the importance of a false-positive versus a
false-negative classification. The user determines the value for the
false-positive rate (here defined as the percentage of non-
tuberculosis samples that will be wrongly classified as M.
tuberculosis) in the Receiver Operating Characteristic (ROC)
curve [17]. The ROC curve describes the relationship between
the false-positive rate and the true-positive rate (the percentage of
M. tuberculosis samples correctly classified as MTB). Therefore, a
decision on the acceptable false-positive rate implicitly establishes
a value for the true-positive rate. Once the false-positive rate (or
the true-positive rate) has been set, a threshold value is obtained. A
value of V below the threshold indicates the presence of an MTB,
whereas a value of V above the threshold indicates the presence of
an NTM. Hence, compounds with negativebivalues tend to be
dominant in the MTB complex group; while positivebivalues
indicate the compounds have a higher probability of being found
in the NTM group. For cases where the sensitivity (true-positive
rate) and specificity (true-negative rate) are equally important, the
threshold value for V is 0.55. In this case, both sensitivity and
specificity are 95%.
Ethical approval
This study was approved by the Health Research Ethics
Committee at Stellenbosch University, South Africa (reference
number N06/09/186).
Results and Discussion
The 56 samples from the Netherlands (Testset-1) consisted of 39
MTB complex strains and 17 opportunistic NTM strains (Table 1).
The demographics and clinical characteristics of the population of
origin for these samples were not collected, but the strains were
representative of those found in the Netherlands. The 56 strains
were tested blindly using our THM-GC-MS method. The results
using the 20-compound model at the threshold value of 0.55 are
summarized in Table 4. Fingerprint patterns of the normalized
Table 3. Compounds identified as relevant for the differentiation of NTM and MTB strains.
No.
Retention
time (min) Name of compounds FAMEs1 m/z Beta-coefficients
1 25.01 Methyl tetradecanoate (C14) C15H30O2 74 3.305
2 29.07 9-Hexadecenoic acid, methyl ester C17H32O2 83 0.863
3 29.48 Hexadecanoic acid, methyl ester (C16) C17H34O2 87 1.634
4 30.75 1-Nonadecene C19H38 97 1.278
5 31.40 Heptadecanoic acid, methyl ester (C17) C18H36O2 74 22.819
6 32.75 9-Octadecenoic acid (Z)-, methyl ester C19H36O2 69 1.153
7 33.33 Octadecanoic acid, methyl ester (C18) C19H38O2 298 20.712
8 34.02 Octadecanoic acid, 10-methyl-, methyl ester(TBSA) C20H40O2 312 0.034
9 36.50 alpha-D-Glucopyranoside, 2,3,4,6-tetra-O-methyl-
alpha-D-glucopyranosyl 2,3,4,6-tetra-O-methyl
C20H38O11 71 21.112
10 40.17 Docosanoic acid, methyl ester (C22) C23H46O2 354 0.942
11 43.22 Tetracosanoic acid, methyl ester (C24) C25H50O2 382 3.563
12 43.94 Unknown fatty acid – 88 20.580
13 44.09 Tetracosanoic acid, 2,4,6-trimethyl-, methyl ester (C27) C28H56O2 101 2.966
14 44.23 Tetracosanoic acid, 2,4,6,8-tetramethyl-, methyl ester (C28) C29H58O2 101 2.961
15 44.70 Pentacosanoic acid, methyl ester (C25) C26H52O2 87 20.965
16 46.12 Hexacosanoic acid, methyl ester (C26) C27H54O2 410 26.948
17 46.88 Hexacosanoic acid, 2,4,6-trimethyl-, methyl ester (C29) C30H60O2 101 22.025
18 47.01 Hexacosanoic acid, 2,4,6,8-tetramethyl-, methyl ester (C30) C31H62O2 101 21.935
19 49.55 Octacosanoic acid, 2,4,6,8-tetramethyl-, methyl ester (A)2 (C32) C33H66O2 101 20.899
20 49.66 Octacosanoic acid, 2,4,6,8-tetramethyl-, methyl ester (B)2 (C32) C33H66O2 101 20.705
1FAMEs = Fatty Acid Methyl Esters.
2A and 2B C32 mycocerosate = Two isomers of C32 mycocerosate.
doi:10.1371/journal.pone.0076263.t003
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areas of the 20 compounds for some representative strains are
given in Figure 1.
The THM-GC-MS patterns of MTB strains differed notably
from those of most NTM strains. We have shown in Figure 2
representative examples of the THM-GC-MS chromatograms for
A: M. tuberculosis, B: M. avium, C: M. marinum, D: M. kansasii.
Clearly MTB strains contained the mycocerosate markers
(compounds 17–20 in Table 3). The mycoserates, breakdown
products of phthiocerol dimycocerosates (PDIMs), were the most
useful for distinguishing between NTM and MTB, since most
NTM lack these markers. However, we identified a group of
opportunistic NTM mycobacteria e.g. M. kansasii that have a
pattern of mycocerosate markers very similar to that of the MTB
complex. The identification of these NTM strains posed a
challenge to our model. Therefore, we could split the NTM
strains into two subsets, one with a pattern for the 20 target
compounds which clearly differed from MTB complex strains
(Figures 1b and 1c compared with 1a), and another subset which
had a pattern that was rather similar to the MTB complex
(Figures 1d and 1e compared with 1a). In Figure 1c, the fingerprint
pattern of the normalized areas of the 20 compounds is given for
M. marinum. High levels of mycocerosate markers 13 and 14 and
low levels of markers 16 and 17 were observed compared to the
MTB strains; markers 19 and 20 were not detected. These features
enabled correct classification of M. marinum as NTM by our model.
Testset-1 contained two M. kansasii type I strains (Figures 1d and
1e). These strains showed a marker pattern similar to the MTB
strains, especially for the mycocerosates (markers 13, 14 and 17–
20). Compounds 17–20 are important markers for MTB since they
have negative beta coefficients (see Table 3). One M. kansasii type I
strain was correctly classified as NTM (Figure 1d) but the other
strain (Figure 1e) was misclassified as MTB by our model. When
the level of any of the marker compounds 17–20 is higher than a
certain threshold (normalized areas of markers 17–18.10% and
normalized areas of markers 19–20.3% as seen in Figure 1e), the
strain is wrongly classified as MTB complex. As a result, for
Testset-1, all 39 strains belonging to the MTB complex (including
M. tuberculosis, M. africanum, M. bovis and M. bovis BCG) were
correctly classified, as well as all but one (M. kansasii) of the 16
strains of NTM. With these strains from the Netherlands, the
model had 100% sensitivity (the percentage of correctly identified
MTB strains) and 94% specificity (the percentage correctly
identified NTM strains). The accuracy was thus 98%.
In the samples from South Africa (Testset-2), using THM-GC-
MS and our 20-compound model, all 12 NTM isolates were
correctly identified (see Table 5). Eighty of the 91 MTB (88%)
isolates were classified correctly. The remaining 11 isolates
(identified by the Bioline test and 16S rRNA sequencing as
belonging to the MTB complex) were misclassified as NTM by our
model. For Testset-2, the sensitivity was 88%, specificity was
100% and accuracy was 90%. The poorer performance of our
model with these samples can be attributed to the very different
geographical origin of the samples used for the training set and the
test set. The samples from the training set came from the
Netherlands whereas the samples from the test set came from
South Africa. The fingerprint patterns of the normalized areas of
the 20 compounds are given for some representative strains from
South Africa in Figure 3. In Figures 3a and b, two different MTB
strains are shown and the pattern of an NTM is shown in
Figure 3c. All three were correctly classified in our model. Five of
the 11 misclassified MTB isolates are shown in Figure 3d–3h.
These strains were rich in compound 3 with concentrations $
60%. The concentrations of the mycocerosate marker compounds
17–20 were very low. The b-coefficient values of the 20
compounds in Table 3 show that hexacosanoic acid (compound
16) and the mycocerosate markers (17–20) are important markers
for the MTB complex. In the strains shown in Figure 3d-3h the
low levels of these markers resulted in their misclassification as
Table 4. Results of the analysis of 56 mycobacterial strains from patients in the Netherlands using THM-GC-MS and the 20-
compound model.
Mycobacterial species/strain Classification by THM-GC-MS1 using the 20- compound model
33 strains M. tuberculosis 33 MTB2 complex
2 strains M. africanum 2 MTB complex
2 strains M. bovis spp bovis 2 MTB complex
2 strains M. bovis BCG 2 MTB complex
2 strains M. avium complex 2 NTM3
2 strains M. chelonae complex 2 NTM
2 strains M. fortuitum complex 2 NTM
2 strains M. gordonae 2 NTM
2 strains M. malmoense 2 NTM
1 strain M. kansasii type I 1 NTM
1 strain M. kansasii type I 1 MTB complex
1 strain M. abscessus 1 NTM
1 strain M. haemophilum 1 NTM
1 strain M. marinum 1 NTM
1 strain M. simiae 1 NTM
1 strain M. intracellulare 1 NTM
1THM-GC-MS = Thermally-assisted hydrolysis and methylation gas chromatography-mass spectrometry.
2MTB complex = M. tuberculosis complex.
3NTM = Non-tuberculous mycobacteria.
doi:10.1371/journal.pone.0076263.t004
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NTM strains. It is relevant to note that our model uses information
about all 20 compounds. However, the most important com-
pounds for the identification of MTB are compounds 16–20. If
these are present in an MTB strain at very low levels or are below
the detection limit, the model will misclassify the MTB as NTM.
The mycocerosate markers 13, 14, 17–20 (Table 3) have also
been found by other researchers to be relevant MTB markers
[19,20]. However, we have found some of these markers are also
present in some other pathogenic and opportunistic mycobacteria
such as M. kansasii, M. marinum, M. gastri, M. ulcerans and M. leprae.
Mycocerosates are multimethyl branched fatty acids present in
phthiocerol dimycocerosates (PDIMs), diacyltrehaloses (DATs),
polyacyltrehaloses (PATs) and phenolphthiocerol dimycocerosates
(PGLs) [21] and are released by the THM treatment [18]. The
PDIMs are highly stable waxes, composed of mixtures of long-
chain mycocerosic acids esterified to the phthiocerols, long-chain
C34 and C36 diols [20]. The differences in the amount of PDIMs
in various M. tuberculosis strains and the fact that PDIMs are also
present in a few strains of NTM may potentially give rise to
confusion if PDIMs alone are used as the feature to distinguish
MTB from NTM. Recently, O’Sullivan and coworkers used
THM-GC-MS to look for mycoserates (with markers correspond-
ing with our compounds 17–20) in sputum [22]. Their method
had a sensitivity of only 61% with a specificity of 71% to detect
MTB in 395 sputum samples from Zimbabwe [22]. Our own
study suggests that this rather poor sensitivity may be due to the
very low levels of mycocerosates found in some MTB strains. On
the other hand, as noted by O’Sullivan and coworkers, the
presence of high levels of matrix compounds from sputum which
elute at similar retention times can easily result in false positive and
false negative results, and hence a low specificity and sensitivity
[22]. With sputum, overloading of the GC-MS is a potential
problem and the inherent lack of robustness of GC-MS may
render the approach, as it stands, unsuitable for routine use in
diagnostic laboratories.
The performance of our model for the Dutch testset-1 was
similar to that achieved previously when measured with the Dutch
training and validation set [17]. In the present study the results for
the South African samples were slightly less accurate, most likely
because the training set used to establish the model lacked strains
from South Africa. For optimum performance the training set used
to derive the model should consist of locally occurring strains and
should include an adequate number of NTMs (preferably
approximately 50%). However, in our model development only
12 NTM strains were available from South Africa, which
precluded us from building a more location-specific model. In a
recent study Olivier and Loots found that GC-MS and multivar-
iate statistical analysis could be used to distinguish M. kansasii, M.
avium, M. tuberculosis and M. bovis from each other using 12
metabolite markers [23]. They used a modified Bligh-Dyer
Figure 1. Fingerprint patterns of the normalized areas of the 20 markers in samples from the Netherlands. The graph shows the
fingerprint patterns of the normalized areas of 20 marker compounds in different mycobacteria from the Netherlands with (A) M. tuberculosis, (B) M.
gordonae, (C) M. marinum, and (D) and (E) two M. kansasii type I strains. Case (A) belongs to the MTB group; cases (B–E) belong to the NTM group.
Compounds 1–20 are identified in Table 3.
doi:10.1371/journal.pone.0076263.g001
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extraction, methylation under basic conditions, followed by
hexane extraction. Three of their markers (C17, TBSA and C32
mycocerosate) were the same ones we found using THM-GC-MS.
Our method has the advantage over theirs that it needs no sample
treatment since suspensions of heat inactivated mycobacteria can
be analyzed directly. Also, our fully-automated procedure makes
the method robust and easy to perform. O’Sullivan and coworkers
used a methanol/petroleum-ether extraction method [22]. We
have run a petroleum ether extract of mycobacteria through the
THM-GC-MS and compared the results with those obtained
using our simple extraction method (data not shown). The patterns
were the same, confirming that the efficiency of our approach is
the same as that for petroleum ether extraction.
Figure 2. Representative examples of the THM-GC-MS chromatograms. Chromatograms are shown for A: M. tuberculosis, B: M. avium, C: M.
marinum, D: M. kansasii.
doi:10.1371/journal.pone.0076263.g002
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Table 5. Results of the analysis of 103 primary isolates from patients from Stellenbosch, South Africa using THM-GC-MS and the
20-compound model.
Mycobacterial species/strain Classification by THM-GC-MS1 using the 20- compound model
80 strains M. tuberculosis 80 strains MTB complex2
11 strains M. tuberculosis 11 NTM3
2 strains M. intracellulare 2 strains NTM
2 unknown strains Bioline test Negative 2 strains NTM
2 strains M. peregrinum/M. septicum 2 strains NTM
2 strains M. avium 2 strains NTM
1 strain M. lentiflavum 1 strain NTM
2 strains M. gordonae 2 strains NTM
1 strain N. shimofusensis 1 strain NTM
1THM-GC-MS = Thermally-assisted hydrolysis and methylation gas chromatography-mass spectrometry.
2MTB complex = M. tuberculosis complex.
3NTM = Non-tuberculous mycobacteria.
doi:10.1371/journal.pone.0076263.t005
Figure 3. Fingerprint patterns of the normalized areas of the 20 markers in samples from South Africa. The graph shows the fingerprint
patterns of the normalized areas of 20 marker compounds in different mycobacteria from South Africa with two representative M. tuberculosis strains
(A & B), one representative NTM strain M. intracellulare (C), five misclassified M. tuberculosis strains (D–H). Note the high value of compound 3 and the
low values of compound 17–20. Compounds 1–20 are identified in Table 3.
doi:10.1371/journal.pone.0076263.g003
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To improve the sensitivity of the model for South African strains
whilst maintaining a high specificity, we built a decision tree using
chemical intuition and experience. The method is based on
normalized areas of the 20 target compounds, ranking them in
order of importance with regard to distinguishing MTB and NTM
strains. The tree diagram obtained this way is given in Figure 4.
The algorithm uses the normalized areas of four mycocerosates
(compounds 17–20), hexacosanoic acid (compound 16), tubercu-
lostearic acid (compound 8), palmitic acid (compound 3) and the
disaccharide (compound 9). The decision tree was built using all
103 samples in Testset-2 from South Africa. We applied the
algorithm to the 100 samples from the Netherlands consisting of
the 56 samples of Testset-1 and 44 samples from the training set
17]. The performance of the newly developed decision tree model
was excellent. All the samples were correctly classified when this
algorithm was used.
In addition to the visual tree model we have explored an
alternative method for obtaining a decision-tree type model based
on a CART (Classification And Regression Trees) method. CART
is a simple but powerful method for multivariate classification and
regression based on a series of subsequent binary partitions using
multivariate data [24]. This method creates an algorithm from a
decision-tree strategy constructed in a systematic way, rather than
by intuition, as described in the previous paragraph. As different
classification trees may be constructed, the ‘‘best’’ tree model is
optimised and further ‘‘pruned’’ using a cross-validation strategy.
To perform the optimization based on a cross-validation is crucial,
since tree methods are prone to over-fitting. Also, care should be
taken to avoid over-optimistic models.
We fitted two CART models. For the first model we considered
the data set consisting of 15 MTB complex strains and 29 NTM
strains from the Netherlands used in our previous study [17]. We
used this data set for calibration and cross-validation. The
optimised tree model (after cross-validation) is shown in
Figure 5a. The model is extremely simple: it only uses two
compounds, #16 and #1, which, as expected, have one of the
lowest and highest b-coefficients respectively (Table 3). The model
yielded an overall accuracy (cross-validated) of 95% (similar to the
method based on the b-coefficients, Table 3). When applied to
Testset-1 the accuracy was 96%. Indeed a good accuracy is
expected, since the Testset-1 consists of samples from the same
geographical region. As with our other models, when this model
was applied to Testset-2, the accuracy decreased to 90%.
Figure 5b depicts the CART model using the data sets derived
from all 203 samples together as training and validation sets. The
model has been optimised by cross-validation, yielding an
accuracy of 99.5% (cross-validated). It follows that, in agreement
with the model shown in Figure 4, it is possible to construct a
Figure 4. Algorithm derived using manual inspection of 103 samples from South Africa. The graph shows a decision tree for the
differentiation of M. tuberculosis complex and non-tuberculous mycobacteria.
doi:10.1371/journal.pone.0076263.g004
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classification model with nearly 100% accuracy. Furthermore, as
this model has been fitted using data from different geographical
origins, the high degree of accuracy suggests that it is possible to
create a global model which is applicable to different geographical
regions. The CART model from Figure 5b makes use particularly
of compounds #16 and #18 and is also very simple. Compound
#16 was a crucial element in the manual decision tree proposed in
Figure 4. Compounds #17–20 were also used in that model. As
these compounds are normally correlated, the CART model finds
it optimal to use only one of them as a classifier, confirming the
usefulness of the algorithm depicted in Figure 4. Moreover, as the
accuracy of the CART model was determined after cross-
validation, there is more certainty that our high accuracy is not
over-optimistic. The fact that the degree of accuracy obtained by
cross-validation in Figure 5a is similar to the one obtained with the
Testset-1 can also be considered as an indirect proof that the
accuracy of the model depicted in Figure 5b is not over-optimistic.
The use of a subset of the 20 compounds (as suggested with the
manual decision tree model and with the CART models) does not
mean that the peak areas of the compounds not participating in
those models are not relevant. This is because the tree models
make use of normalized peak areas, i.e. the areas of every
compound are normalized to make the sum of the 20 compound
areas equal to 1. Hence, in practice, the user should still measure
experimentally the peak area of the 20 compounds, in order to
normalize the values correctly. In principle, it could be possible to
fit a tree model using information from the two compounds
participating in the model only (normalization within the two
compounds). From an experimental perspective, this would be
highly attractive, since then the experimental measurement of the
remaining 18 compounds could be skipped. However, when the
tree model was fitted in this way, its performance was significantly
reduced (from 99% to 86.5%).
We plan to explore if the combination of our 20-compound
model, the decision tree and CART models can be applied to
identify and classify MTB and NTM strains directly in sputum. If
so it would pave the way to the development of a much simpler,
high-throughput test to identify MTB or NTM directly in sputum.
This panel of 20 compounds offers the possibility of further
developments which could result in a simple test for field use in
resource-constrained countries.
Conclusion
Conventional methods for the differentiation of MTB from
NTM still suffer from the limitations of speed, sensitivity and
specificity. Our fully automated THM-GC-MS approach with the
20-compound model is a promising tool to differentiate MTB and
NTM. Excellent results can be obtained when the training and
validation sets originate from the same geographical settings. If the
sample set is obtained from a different area the results may not be
as good, although our method still achieved a sensitivity of 88%
and specificity of 100%. We have derived two types of tree models
to solve this problem. One algorithm was constructed using
manual inspection of the data, which enabled correct classification
of all 103 samples from South Africa and 100 samples from the
Netherlands, i.e. 100% sensitivity and specificity. Another tree was
fitted using a CART model. This last model was extremely simple
(only two compounds included), yet highly accurate (99.5%
accuracy) when the accuracy was tested using cross-validation.
Although promising, these findings were derived from strains from
The Netherlands and South Africa only. Future studies using
strains from different areas are needed to corroborate these
findings. Our final goal is to develop a micro GC and portable
detector to detect and differentiate MTB and NTM directly in
sputum.
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